Renovorx reports initial revenues from renovocath® commercialization, and provides update on ongoing pivotal phase iii tiger-pac clinical trial

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared drug-delivery device, today announced its financial results and business updates for the fourth quarter and full year ended december 31, 2024. “the fourth quarter of 2024 marks a significant milestone in our company history as we have generated our first revenue from sa.
RNXT Ratings Summary
RNXT Quant Ranking